A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients

Silvennoinen, R (author)

Waage, A (author)

Peceliunas, V (author)

show more...

Schjesvold, F (author)

Anttila, P (author)

Uttervall, K (author)

Karolinska Institutet

Saily, M (author)

Putkonen, M (author)

Carlson, K (author)

Haukas, E (author)

Sankelo, M (author)

Partanen, A (author)

Szatkowski, D (author)

Hansson, M (author)

Marttila, A (author)

Svensson, R (author)

Axelsson, P (author)

Lauri, B (author)

Mikkola, M (author)

Karlsson, C (author)

Abelsson, J (author)

Ahlstrand, E (author)

Sikio, A (author)

Nahi, H (author)

Karolinska Institutet

show less...

 (creator_code:org_t)

2022

2022

English.

In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - 2152-2650. ; 22, s. S157-S157

Related links:

http://kipublication...

• Conference paper (other academic/artistic)